Showing 4731-4740 of 9923 results for "".
- UCB Presents New Data for Cimzia, Investigational Bimekizumabhttps://practicaldermatology.com/news/ucb-presents-new-data-for-cimzia-investigational-bimekizumab/2460193/Data on the use of UCB’s Cimzia (certolizumab pegol), in psoriasis and psoriatic arthritis (PsA) as well as Phase 2 data for the company’s investigational molecule bimekizumab have been presented at the 28thEuropean Academy of Dermatology and Venereology congress (EADV) in Madrid. Cim
- National Eczema Association's New Campaign Exposes The “Real Eczema”https://practicaldermatology.com/news/national-eczema-associations-new-campaign-exposes-the-real-eczema/2460160/October's Eczema Awareness Month efforts will focus on unhiding the realities of eczema with the National Eczema Association's (NEA) #TheRealEczema campaign. The new campaign includes a video, "The Real Eczema," featur
- Modernizing Medicine: New Capabilities Address Price Transparency, Patient Engagementhttps://practicaldermatology.com/news/modernizing-medicine-new-capabilities-address-price-transparency-patient-engagement/2460100/Modernizing Medicine® will showcase new and enhanced capabilities for price transparency, digital patient engagement and more to the company’s electronic health records (EHR) platform, EMA®, and Practice Management system at the American Academy of Dermatology (AAD) 2019 S
- Burt's Bees Data at WCD Highlights Power of Naturalshttps://practicaldermatology.com/news/burts-bees-data-at-wcd-highlights-power-of-naturals/2460062/New research from Burt's Bees supports findings related to the skin's composition and the role of nature-based regimens to protect the skin against common environmental stressors. The studies will be presented at the 24th World Congress of Dermatology (WCD) Meeting in Milan
- Get to Know the Dermatology Hall of Fame's 2019 Inaugural Class of Inducteeshttps://practicaldermatology.com/news/meet-the-dermatology-hall-of-fame-2019-inaugural-class-of-inductees/2459984/The 10 individuals inducted into the Dermatology Hall of Fame’s 2019 Inaugural Class are: Albert Bernard Ackerman, M.D., the author of “Histologic Diagnosis of Inflammatory Skin Diseases” and recipient of the American Academy of Dermatology’s Master Dermatologist
- LEO Pharma Focuses on Translational Medicine, Appoints Dr. Adam B. Raff as Director & Medical Advisorhttps://practicaldermatology.com/news/leo-pharma-strengthens-focus-on-translational-medicine-with-appointment-of-dr-adam-b-raff-as-director-medical-advisor/2459942/LEO Pharma has appointed Adam B. Raff, MD, PhD as Director and Medical Advisor in Translational Medicine, effective January 28. Dr. Raff’s primary objective will be to support LEO Pharma’s ambitions to advance science within dermatology through translational medicine, the company says
- Leadership Changes Announced for Cuterahttps://practicaldermatology.com/news/leadership-changes-announced-for-cutera/2459944/Cutera, Inc.'s James Reinstein resigned as President, Chief Executive Officer, and member of its Board of Directors, effective immediately. The Board has appointed Cutera’s Chief Operating Officer, Jason Richey, as Interim CEO. J. Daniel Plants, Chairman of Cutera, said: &
- ASDS Announces 2018 President's Award Recipientshttps://practicaldermatology.com/news/asds-announces-2018-presidents-award-recipients/2457565/In her final act as president this week, Lisa M. Donofrio, MD, recognizes four members of the American Society for Dermatologic Surgery (ASDS) with the President’s Award at the Society’s Annual Meeting. “One of the wonderful gifts about being president of an organization
- Trevi Therapeutics Appoints Yann Mazabraud as Chief Commercial Officerhttps://practicaldermatology.com/news/trevi-therapeutics-appoints-yann-mazabraud-as-chief-commercial-officer/2457685/Trevi Therapeutics, Inc. has named Yann Mazabraud as its Chief Commercial Officer and Head of International. Mr. Mazabraud will join Trevi’s senior management team and be responsible for overseeing Trevi’s commercial strategy and international operations.
- FDA Frowns on Evolus' Botox Rivalhttps://practicaldermatology.com/news/fda-frowns-on-evolus-botox-rival/2457763/The U.S Food and Drug Administration did not approve DWP-450, Evolus Inc's rival product to Allergan Plc's Botox, due to chemistry and manufacturing issues. As a result, the company pushed its estimate for the launch of the drug to the spring of next year. Read more